Wedbush analyst David Nierengarten downgraded iKena Oncology to Neutral from Outperform with a price target of $2, down from $8. The analyst cites the discontinuation of lead program IK-930, the company’s TEAD1 selective inhibitor for the treatment of hippo mutated solid tumors, for the downgrade. While not explicitly stated, the discontinuation is due to challenges in developing a very targeted agent in less common tumor types, and the expenses associated with combination studies, the analyst tells investors in a research note. The firm is moving to the sidelines until management discloses more data and development plans for IK-595 given the competition in the space.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IKNA:
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue